| Hazard Information | Back Directory | [Uses]
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D)[1][2]. | [in vivo]
Volagidemab (5 mg/kg, s.c.) suppresses type 1 diabetes phenotype in Alloxan-induced diabetic mice[2].
| Animal Model: | Alloxan-induced diabetic mice [2] | | Dosage: | 5 mg/kg | | Administration: | Subcutaneous injection (s.c.) | | Result: | Reduced phosphorylated CREB protein and PEPCK protein expression to nondiabetic levels. |
| [References]
[1] Pettus J, et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 Oct;28(10):2092-2099. DOI:10.1038/s41591-022-02011-x
[2] Wang MY, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2503-8. DOI:10.1073/pnas.1424934112 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|